Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 4942 | 417716-92-8 |
Dose | Unit | Route |
---|---|---|
18 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
March 26, 2015 | PMDA | Eisai Co., Ltd. | |
Feb. 13, 2015 | FDA | EISAI INC | |
May 28, 2015 | EMA | Eisai Europe Ltd |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hypertension | 829.31 | 24.54 | 512 | 9391 | 210691 | 50384530 |
Malignant neoplasm progression | 744.18 | 24.54 | 329 | 9574 | 67795 | 50527426 |
Proteinuria | 527.43 | 24.54 | 175 | 9728 | 16422 | 50578799 |
Decreased appetite | 387.91 | 24.54 | 317 | 9586 | 200606 | 50394615 |
Palmar-plantar erythrodysaesthesia syndrome | 319.00 | 24.54 | 127 | 9776 | 19971 | 50575250 |
Hepatic encephalopathy | 237.14 | 24.54 | 84 | 9819 | 9552 | 50585669 |
Diarrhoea | 197.35 | 24.54 | 384 | 9519 | 588092 | 50007129 |
Platelet count decreased | 152.94 | 24.54 | 139 | 9764 | 100587 | 50494634 |
Blood pressure increased | 151.92 | 24.54 | 157 | 9746 | 132975 | 50462246 |
Hypothyroidism | 130.61 | 24.54 | 82 | 9821 | 34043 | 50561178 |
Cholecystitis | 98.50 | 24.54 | 50 | 9853 | 13821 | 50581400 |
Drug ineffective | 95.62 | 24.54 | 22 | 9881 | 819311 | 49775910 |
Stomatitis | 90.20 | 24.54 | 105 | 9798 | 101239 | 50493982 |
Tumour haemorrhage | 88.95 | 24.54 | 25 | 9878 | 1330 | 50593891 |
Tracheal fistula | 67.95 | 24.54 | 11 | 9892 | 32 | 50595189 |
Fatigue | 67.84 | 24.54 | 295 | 9608 | 707306 | 49887915 |
Pneumothorax | 67.29 | 24.54 | 39 | 9864 | 13995 | 50581226 |
Fistula | 62.38 | 24.54 | 31 | 9872 | 8187 | 50587034 |
Dysphonia | 61.50 | 24.54 | 55 | 9848 | 38837 | 50556384 |
Oral pain | 51.07 | 24.54 | 41 | 9862 | 24992 | 50570229 |
Gastrointestinal perforation | 50.78 | 24.54 | 20 | 9883 | 3041 | 50592180 |
Dehydration | 48.63 | 24.54 | 98 | 9805 | 152351 | 50442870 |
Nephrotic syndrome | 48.47 | 24.54 | 22 | 9881 | 4748 | 50590473 |
Arterial haemorrhage | 47.69 | 24.54 | 16 | 9887 | 1541 | 50593680 |
Ascites | 47.58 | 24.54 | 46 | 9857 | 35815 | 50559406 |
Blood thyroid stimulating hormone increased | 46.29 | 24.54 | 23 | 9880 | 6069 | 50589152 |
Protein urine present | 45.96 | 24.54 | 22 | 9881 | 5355 | 50589866 |
Condition aggravated | 43.58 | 24.54 | 4 | 9899 | 297054 | 50298167 |
Weight decreased | 40.90 | 24.54 | 115 | 9788 | 221130 | 50374091 |
Posterior reversible encephalopathy syndrome | 40.52 | 24.54 | 29 | 9874 | 14899 | 50580322 |
Cerebral haemorrhage | 40.29 | 24.54 | 37 | 9866 | 27015 | 50568206 |
Hepatic function abnormal | 37.96 | 24.54 | 39 | 9864 | 32642 | 50562579 |
Vomiting | 37.86 | 24.54 | 184 | 9719 | 460574 | 50134647 |
Malaise | 37.47 | 24.54 | 147 | 9756 | 335385 | 50259836 |
Cholecystitis acute | 37.42 | 24.54 | 21 | 9882 | 7085 | 50588136 |
Drug hypersensitivity | 35.19 | 24.54 | 4 | 9899 | 251006 | 50344215 |
Epistaxis | 34.66 | 24.54 | 52 | 9851 | 63902 | 50531319 |
Colitis | 34.34 | 24.54 | 40 | 9863 | 38489 | 50556732 |
Oesophageal fistula | 32.35 | 24.54 | 7 | 9896 | 123 | 50595098 |
Intestinal perforation | 32.27 | 24.54 | 22 | 9881 | 10457 | 50584764 |
Thrombocytopenia | 31.46 | 24.54 | 74 | 9829 | 127599 | 50467622 |
Tracheal haemorrhage | 31.45 | 24.54 | 7 | 9896 | 141 | 50595080 |
Primary adrenal insufficiency | 31.33 | 24.54 | 6 | 9897 | 55 | 50595166 |
Hypersensitivity | 31.26 | 24.54 | 3 | 9900 | 215158 | 50380063 |
Immune-mediated hepatitis | 30.53 | 24.54 | 10 | 9893 | 894 | 50594327 |
Hypertensive crisis | 29.97 | 24.54 | 23 | 9880 | 13131 | 50582090 |
Nausea | 28.01 | 24.54 | 234 | 9669 | 705164 | 49890057 |
Oesophageal perforation | 27.24 | 24.54 | 7 | 9896 | 264 | 50594957 |
Weight increased | 26.41 | 24.54 | 4 | 9899 | 201887 | 50393334 |
Ammonia increased | 26.40 | 24.54 | 14 | 9889 | 4227 | 50590994 |
Swelling | 26.23 | 24.54 | 4 | 9899 | 200868 | 50394353 |
Large intestine perforation | 26.13 | 24.54 | 17 | 9886 | 7477 | 50587744 |
Oesophageal varices haemorrhage | 25.40 | 24.54 | 9 | 9894 | 1021 | 50594200 |
Product use in unapproved indication | 25.19 | 24.54 | 64 | 9839 | 115755 | 50479466 |
Off label use | 24.86 | 24.54 | 34 | 9869 | 474392 | 50120829 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Decreased appetite | 715.98 | 23.45 | 562 | 12896 | 144780 | 29416289 |
Hepatic encephalopathy | 708.52 | 23.45 | 254 | 13204 | 12781 | 29548288 |
Malignant neoplasm progression | 692.71 | 23.45 | 425 | 13033 | 73434 | 29487635 |
Proteinuria | 510.70 | 23.45 | 211 | 13247 | 15593 | 29545476 |
Palmar-plantar erythrodysaesthesia syndrome | 473.28 | 23.45 | 196 | 13262 | 14563 | 29546506 |
Hypertension | 451.31 | 23.45 | 393 | 13065 | 116221 | 29444848 |
Diarrhoea | 351.90 | 23.45 | 576 | 12882 | 332122 | 29228947 |
Hypothyroidism | 233.18 | 23.45 | 123 | 13335 | 15783 | 29545286 |
Tumour haemorrhage | 199.63 | 23.45 | 65 | 13393 | 2420 | 29558649 |
Liver carcinoma ruptured | 174.05 | 23.45 | 34 | 13424 | 131 | 29560938 |
Fatigue | 165.36 | 23.45 | 410 | 13048 | 316411 | 29244658 |
Blood pressure increased | 143.25 | 23.45 | 172 | 13286 | 73631 | 29487438 |
Dysphonia | 140.73 | 23.45 | 95 | 13363 | 19101 | 29541968 |
Ascites | 114.59 | 23.45 | 110 | 13348 | 36509 | 29524560 |
Malaise | 112.20 | 23.45 | 233 | 13225 | 159369 | 29401700 |
Oesophageal varices haemorrhage | 111.14 | 23.45 | 43 | 13415 | 2659 | 29558410 |
Hepatic failure | 97.32 | 23.45 | 94 | 13364 | 31418 | 29529651 |
Drug ineffective | 95.70 | 23.45 | 24 | 13434 | 363146 | 29197923 |
Ammonia increased | 88.27 | 23.45 | 41 | 13417 | 3990 | 29557079 |
Stomatitis | 82.76 | 23.45 | 93 | 13365 | 37020 | 29524049 |
Cholecystitis | 78.29 | 23.45 | 50 | 13408 | 9147 | 29551922 |
Pneumothorax | 72.34 | 23.45 | 59 | 13399 | 15783 | 29545286 |
Blood bilirubin increased | 70.60 | 23.45 | 82 | 13376 | 33811 | 29527258 |
Cholangitis | 69.22 | 23.45 | 43 | 13415 | 7494 | 29553575 |
Oral pain | 65.64 | 23.45 | 45 | 13413 | 9262 | 29551807 |
Dehydration | 61.93 | 23.45 | 151 | 13307 | 114597 | 29446472 |
Hepatic function abnormal | 60.98 | 23.45 | 82 | 13376 | 39177 | 29521892 |
Blood thyroid stimulating hormone increased | 60.07 | 23.45 | 29 | 13429 | 3076 | 29557993 |
Tumour rupture | 55.66 | 23.45 | 14 | 13444 | 200 | 29560869 |
Epistaxis | 51.77 | 23.45 | 88 | 13370 | 51616 | 29509453 |
Drug interaction | 48.18 | 23.45 | 15 | 13443 | 197370 | 29363699 |
Weight decreased | 47.78 | 23.45 | 164 | 13294 | 150741 | 29410328 |
Toxicity to various agents | 46.51 | 23.45 | 11 | 13447 | 173650 | 29387419 |
Tracheal fistula | 45.83 | 23.45 | 10 | 13448 | 73 | 29560996 |
Portal vein thrombosis | 43.98 | 23.45 | 24 | 13434 | 3285 | 29557784 |
Condition aggravated | 43.94 | 23.45 | 7 | 13451 | 146288 | 29414781 |
Hyperammonaemia | 43.80 | 23.45 | 29 | 13429 | 5634 | 29555435 |
Platelet count decreased | 40.58 | 23.45 | 122 | 13336 | 104550 | 29456519 |
Off label use | 37.83 | 23.45 | 49 | 13409 | 300751 | 29260318 |
Vomiting | 36.84 | 23.45 | 192 | 13266 | 212068 | 29349001 |
Taste disorder | 35.83 | 23.45 | 24 | 13434 | 4752 | 29556317 |
Cholecystitis acute | 35.81 | 23.45 | 25 | 13433 | 5294 | 29555775 |
Gastrointestinal perforation | 34.86 | 23.45 | 21 | 13437 | 3462 | 29557607 |
Thyroiditis | 34.28 | 23.45 | 17 | 13441 | 1911 | 29559158 |
Tracheo-oesophageal fistula | 33.52 | 23.45 | 11 | 13447 | 419 | 29560650 |
Immune-mediated hepatitis | 31.78 | 23.45 | 15 | 13443 | 1512 | 29559557 |
Liver abscess | 30.53 | 23.45 | 19 | 13439 | 3319 | 29557750 |
Neutropenia | 30.38 | 23.45 | 11 | 13447 | 131700 | 29429369 |
Rhythm idioventricular | 29.39 | 23.45 | 9 | 13449 | 273 | 29560796 |
Protein urine present | 29.15 | 23.45 | 21 | 13437 | 4673 | 29556396 |
Liver disorder | 26.14 | 23.45 | 46 | 13412 | 27703 | 29533366 |
Nausea | 25.98 | 23.45 | 222 | 13236 | 289033 | 29272036 |
Protein induced by vitamin K absence or antagonist II increased | 25.86 | 23.45 | 5 | 13453 | 18 | 29561051 |
Haemobilia | 24.50 | 23.45 | 8 | 13450 | 300 | 29560769 |
Arterial haemorrhage | 24.20 | 23.45 | 10 | 13448 | 734 | 29560335 |
Nephrotic syndrome | 23.62 | 23.45 | 21 | 13437 | 6307 | 29554762 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Malignant neoplasm progression | 1170.76 | 22.09 | 574 | 16205 | 112297 | 64369656 |
Hypertension | 1026.93 | 22.09 | 704 | 16075 | 258557 | 64223396 |
Proteinuria | 843.20 | 22.09 | 304 | 16475 | 27419 | 64454534 |
Decreased appetite | 748.29 | 22.09 | 602 | 16177 | 280687 | 64201266 |
Hepatic encephalopathy | 662.85 | 22.09 | 237 | 16542 | 20829 | 64461124 |
Palmar-plantar erythrodysaesthesia syndrome | 611.45 | 22.09 | 243 | 16536 | 28576 | 64453377 |
Diarrhoea | 315.93 | 22.09 | 622 | 16157 | 722082 | 63759871 |
Tumour haemorrhage | 270.38 | 22.09 | 78 | 16701 | 3415 | 64478538 |
Hypothyroidism | 267.67 | 22.09 | 153 | 16626 | 40304 | 64441649 |
Drug ineffective | 156.85 | 22.09 | 18 | 16761 | 840229 | 63641724 |
Pneumothorax | 152.91 | 22.09 | 89 | 16690 | 24209 | 64457744 |
Cholecystitis | 145.37 | 22.09 | 80 | 16699 | 19556 | 64462397 |
Liver carcinoma ruptured | 139.55 | 22.09 | 26 | 16753 | 146 | 64481807 |
Platelet count decreased | 135.30 | 22.09 | 191 | 16588 | 167520 | 64314433 |
Ascites | 127.32 | 22.09 | 115 | 16664 | 61886 | 64420067 |
Oesophageal varices haemorrhage | 110.85 | 22.09 | 40 | 16739 | 3589 | 64478364 |
Blood pressure increased | 108.50 | 22.09 | 175 | 16604 | 172377 | 64309576 |
Tracheal fistula | 102.86 | 22.09 | 19 | 16760 | 101 | 64481852 |
Malaise | 98.82 | 22.09 | 275 | 16504 | 395972 | 64085981 |
Dysphonia | 93.17 | 22.09 | 85 | 16694 | 46297 | 64435656 |
Hepatic function abnormal | 90.40 | 22.09 | 97 | 16682 | 64216 | 64417737 |
Blood bilirubin increased | 86.57 | 22.09 | 90 | 16689 | 57463 | 64424490 |
Dehydration | 78.86 | 22.09 | 174 | 16605 | 216589 | 64265364 |
Blood thyroid stimulating hormone increased | 76.09 | 22.09 | 38 | 16741 | 7616 | 64474337 |
Cholecystitis acute | 75.14 | 22.09 | 43 | 16736 | 11317 | 64470636 |
Tracheo-oesophageal fistula | 70.15 | 22.09 | 18 | 16761 | 503 | 64481450 |
Hepatic failure | 69.95 | 22.09 | 79 | 16700 | 55315 | 64426638 |
Arterial haemorrhage | 69.67 | 22.09 | 25 | 16754 | 2206 | 64479747 |
Nephrotic syndrome | 68.11 | 22.09 | 38 | 16741 | 9529 | 64472424 |
Toxicity to various agents | 67.03 | 22.09 | 8 | 16771 | 363505 | 64118448 |
Condition aggravated | 66.73 | 22.09 | 9 | 16770 | 372417 | 64109536 |
Fistula | 64.70 | 22.09 | 37 | 16742 | 9724 | 64472229 |
Stomatitis | 64.53 | 22.09 | 108 | 16671 | 109497 | 64372456 |
Fatigue | 63.12 | 22.09 | 370 | 16409 | 748360 | 63733593 |
Ammonia increased | 61.67 | 22.09 | 32 | 16747 | 6945 | 64475008 |
Gastrointestinal perforation | 60.10 | 22.09 | 29 | 16750 | 5395 | 64476558 |
Immune-mediated hepatitis | 59.78 | 22.09 | 23 | 16756 | 2466 | 64479487 |
Cholangitis | 58.65 | 22.09 | 36 | 16743 | 10766 | 64471187 |
Hyperammonaemia | 51.22 | 22.09 | 32 | 16747 | 9872 | 64472081 |
Portal vein thrombosis | 50.26 | 22.09 | 25 | 16754 | 4966 | 64476987 |
Cerebral haemorrhage | 49.96 | 22.09 | 64 | 16715 | 51026 | 64430927 |
Vomiting | 47.35 | 22.09 | 274 | 16505 | 550843 | 63931110 |
Primary adrenal insufficiency | 44.20 | 22.09 | 9 | 16770 | 85 | 64481868 |
Posterior reversible encephalopathy syndrome | 44.01 | 22.09 | 41 | 16738 | 22905 | 64459048 |
Protein urine present | 43.97 | 22.09 | 28 | 16751 | 8928 | 64473025 |
Hypertensive crisis | 43.75 | 22.09 | 37 | 16742 | 18211 | 64463742 |
Drug interaction | 43.37 | 22.09 | 20 | 16759 | 362063 | 64119890 |
Large intestine perforation | 41.94 | 22.09 | 31 | 16748 | 12573 | 64469380 |
Epistaxis | 41.68 | 22.09 | 84 | 16695 | 98047 | 64383906 |
Weight decreased | 41.15 | 22.09 | 165 | 16614 | 285574 | 64196379 |
Haemoptysis | 41.13 | 22.09 | 57 | 16722 | 48991 | 64432962 |
Weight increased | 41.06 | 22.09 | 4 | 16775 | 213344 | 64268609 |
Hypersensitivity | 39.67 | 22.09 | 3 | 16776 | 196449 | 64285504 |
Intestinal perforation | 38.68 | 22.09 | 32 | 16747 | 15281 | 64466672 |
Drug hypersensitivity | 37.59 | 22.09 | 8 | 16771 | 237807 | 64244146 |
Off label use | 36.78 | 22.09 | 68 | 16711 | 632738 | 63849215 |
Tumour rupture | 36.78 | 22.09 | 10 | 16769 | 351 | 64481602 |
Pneumonitis | 34.22 | 22.09 | 53 | 16726 | 50312 | 64431641 |
Fall | 34.02 | 22.09 | 35 | 16744 | 416791 | 64065162 |
Tumour lysis syndrome | 33.98 | 22.09 | 33 | 16746 | 19407 | 64462546 |
Oesophageal perforation | 33.77 | 22.09 | 12 | 16767 | 1029 | 64480924 |
Oesophageal fistula | 33.49 | 22.09 | 9 | 16770 | 302 | 64481651 |
Cerebral infarction | 33.37 | 22.09 | 47 | 16732 | 40997 | 64440956 |
Thyroiditis | 33.12 | 22.09 | 17 | 16762 | 3607 | 64478346 |
Upper gastrointestinal haemorrhage | 32.68 | 22.09 | 43 | 16736 | 35177 | 64446776 |
Drug intolerance | 32.56 | 22.09 | 5 | 16774 | 187987 | 64293966 |
Pyrexia | 32.38 | 22.09 | 252 | 16527 | 558392 | 63923561 |
Colitis | 32.11 | 22.09 | 56 | 16723 | 58618 | 64423335 |
Product dose omission issue | 29.86 | 22.09 | 7 | 16772 | 194740 | 64287213 |
Liver disorder | 29.29 | 22.09 | 51 | 16728 | 53300 | 64428653 |
Pulmonary embolism | 29.12 | 22.09 | 94 | 16685 | 146262 | 64335691 |
Rhythm idioventricular | 28.87 | 22.09 | 9 | 16770 | 514 | 64481439 |
Cardiac failure | 28.15 | 22.09 | 87 | 16692 | 132286 | 64349667 |
Oral pain | 27.75 | 22.09 | 35 | 16744 | 27458 | 64454495 |
Sinusitis | 27.39 | 22.09 | 3 | 16776 | 145925 | 64336028 |
Adrenal insufficiency | 26.56 | 22.09 | 31 | 16748 | 22456 | 64459497 |
Abdominal pain | 26.52 | 22.09 | 155 | 16624 | 312220 | 64169733 |
Interstitial lung disease | 26.38 | 22.09 | 70 | 16709 | 97662 | 64384291 |
Small intestinal perforation | 26.20 | 22.09 | 13 | 16766 | 2567 | 64479386 |
Overdose | 25.97 | 22.09 | 5 | 16774 | 159561 | 64322392 |
Pancreatitis | 25.26 | 22.09 | 51 | 16728 | 59556 | 64422397 |
Pain | 25.15 | 22.09 | 68 | 16711 | 553443 | 63928510 |
Hyponatraemia | 24.88 | 22.09 | 90 | 16689 | 148249 | 64333704 |
Liver abscess | 24.66 | 22.09 | 16 | 16763 | 5264 | 64476689 |
Cholangitis acute | 24.45 | 22.09 | 10 | 16769 | 1258 | 64480695 |
Renal impairment | 24.44 | 22.09 | 84 | 16695 | 134933 | 64347020 |
Tracheal haemorrhage | 23.57 | 22.09 | 8 | 16771 | 598 | 64481355 |
Hyperthyroidism | 23.06 | 22.09 | 26 | 16753 | 18153 | 64463800 |
Cancer pain | 22.63 | 22.09 | 14 | 16765 | 4243 | 64477710 |
None
Source | Code | Description |
---|---|---|
ATC | L01EX08 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Other protein kinase inhibitors |
FDA MoA | N0000020000 | Receptor Tyrosine Kinase Inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D047428 | Protein Kinase Inhibitors |
FDA EPC | N0000175605 | Kinase Inhibitor |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:62434 | ALK inhibitor |
CHEBI has role | CHEBI:63457 | FGFR inhibitors |
CHEBI has role | CHEBI:65207 | vascular endothelial growth factor receptor inhibitors |
CHEBI has role | CHEBI:71031 | orphan drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Endometrial carcinoma progressing after chemotherapy | indication | 254878006 | DOID:2871 |
Follicular thyroid carcinoma | indication | 255028004 | DOID:3962 |
Papillary thyroid carcinoma | indication | 255029007 | DOID:3969 |
Renal cell carcinoma | indication | 702391001 | DOID:4450 |
Thymic carcinoma | indication | 722670005 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.09 | acidic |
pKa2 | 12.74 | acidic |
pKa3 | 13.02 | acidic |
pKa4 | 4.67 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | 9006256 | July 27, 2027 | METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | 9006256 | July 27, 2027 | METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Feb. 13, 2022 | TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Feb. 13, 2022 | TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Sept. 17, 2022 | TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Sept. 17, 2022 | TREATMENT OF ADVANCED ENDOMETRIAL CARCINOMA THAT IS NOT MICROSATELLITE INSTABILITY-HIGH OR MISMATCH REPAIR DEFICIENT, WHO HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | July 21, 2024 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1 |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | July 21, 2024 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 309/KEYNOTE-775 TO SUPPORT PMR 3696-1 AND 3700-1 |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Aug. 10, 2024 | LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Aug. 10, 2024 | LENVATINIB IN COMBINATION WITH PEMBROLIZUMAB, IS INDICATED FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Dec. 19, 2024 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1 |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Dec. 19, 2024 | REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY E7080-G000-211 TO SUPPORT PMR 2865-1 |
EQ 10MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Aug. 15, 2025 | INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) |
EQ 4MG BASE | LENVIMA | EISAI INC | N206947 | Feb. 13, 2015 | RX | CAPSULE | ORAL | Aug. 15, 2025 | INDICATED FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Proto-oncogene tyrosine-protein kinase receptor Ret | Kinase | INHIBITOR | Ki | 8.82 | CHEMBL | DRUG LABEL | |||
Mast/stem cell growth factor receptor Kit | Kinase | INHIBITOR | IC50 | 7 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Vascular endothelial growth factor receptor 1 | Kinase | INHIBITOR | IC50 | 7.66 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Vascular endothelial growth factor receptor 2 | Kinase | INHIBITOR | IC50 | 8.40 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Vascular endothelial growth factor receptor 3 | Kinase | INHIBITOR | IC50 | 8.28 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Platelet-derived growth factor receptor alpha | Kinase | INHIBITOR | IC50 | 7.29 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Fibroblast growth factor receptor 1 | Kinase | INHIBITOR | IC50 | 7.34 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
Mitogen-activated protein kinase kinase kinase kinase 5 | Kinase | Kd | 5.51 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 7.96 | CHEMBL | |||||
STE20-like serine/threonine-protein kinase | Kinase | Kd | 5.41 | CHEMBL | |||||
Epithelial discoidin domain-containing receptor 1 | Kinase | Kd | 7.34 | CHEMBL | |||||
Protein-tyrosine kinase 6 | Kinase | Kd | 6.76 | CHEMBL | |||||
MAP kinase-activated protein kinase 2 | Kinase | Kd | 7.20 | CHEMBL | |||||
Discoidin domain-containing receptor 2 | Kinase | Kd | 6.66 | CHEMBL | |||||
Ribosyldihydronicotinamide dehydrogenase [quinone] | Enzyme | Kd | 5.82 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase kinase 2 | Kinase | Kd | 6.24 | CHEMBL | |||||
Serine/threonine-protein kinase/endoribonuclease IRE1 | Kinase | Kd | 5.65 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 5 | Kinase | Kd | 5.54 | CHEMBL | |||||
Ferrochelatase, mitochondrial | Enzyme | Kd | 5.55 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 3 | Kinase | Kd | 6.50 | CHEMBL | |||||
Mitogen-activated protein kinase kinase kinase 6 | Kinase | Kd | 5.80 | CHEMBL | |||||
Platelet-derived growth factor receptor beta | Kinase | INHIBITOR | IC50 | 7.41 | SCIENTIFIC LITERATURE | ||||
Epidermal growth factor receptor | Kinase | INHIBITOR | IC50 | 5.19 | SCIENTIFIC LITERATURE | ||||
Aurora kinase B | Kinase | Kd | 5.75 | CHEMBL | |||||
Tyrosine-protein kinase ABL1 | Kinase | Kd | 5.42 | CHEMBL | |||||
Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 6.88 | CHEMBL | |||||
Breakpoint cluster region protein | Kinase | Kd | 5.39 | CHEMBL | |||||
Serine/threonine-protein kinase 10 | Kinase | Kd | 6.10 | CHEMBL | |||||
TRAF2 and NCK-interacting protein kinase | Kinase | Kd | 6.25 | CHEMBL | |||||
Mitogen-activated protein kinase 14 | Kinase | Kd | 6.66 | CHEMBL |
ID | Source |
---|---|
EE083865G2 | UNII |
D09919 | KEGG_DRUG |
4034239 | VUID |
N0000191429 | NUI |
857890-39-2 | SECONDARY_CAS_RN |
4034239 | VANDF |
C2986924 | UMLSCUI |
CHEBI:85994 | CHEBI |
LEV | PDB_CHEM_ID |
CHEMBL1289601 | ChEMBL_ID |
9823820 | PUBCHEM_CID |
DB09078 | DRUGBANK_ID |
CHEMBL2105704 | ChEMBL_ID |
9361 | INN_ID |
C531958 | MESH_SUPPLEMENTAL_RECORD_UI |
7426 | IUPHAR_LIGAND_ID |
1603296 | RXNORM |
232716 | MMSL |
294829 | MMSL |
294831 | MMSL |
30895 | MMSL |
d08346 | MMSL |
714108002 | SNOMEDCT_US |
714109005 | SNOMEDCT_US |
735068004 | SNOMEDCT_US |
015899 | NDDF |
015900 | NDDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-704 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-704 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-708 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-708 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-710 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-710 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-712 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-712 | CAPSULE | 4 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-720 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |
Lenvima | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62856-720 | CAPSULE | 10 mg | ORAL | NDA | 32 sections |